Compensatory Mechanisms in Experimental and Human Parkinsonism: Potential for New Therapies

Handbook of Behavioral Neuroscience

Volumn 20, Issue C, 2010, Pages 641-652

  Bezard, Erwan ^a   Porras, Grégory ^a   Blesa, Javier ^b   Obeso, José A ^b,c  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85016276036     PISSN: 15697339     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-374767-9.00037-8     Document Type: Chapter

References (97)

1. Abercrombie, ED, Bonatz, AE, Zigmond, MJ, Effects of l-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 525 (1990), 36-44.
2. Adams, JR, van Netten, H, Schulzer, M, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 128 (2005), 2777-2785.
3. Agid, Y, Parkinson's disease: pathophysiology. Lancet 337 (1991), 1321-1324.
4. Albin, RL, Young, AB, Penney, JB, The functional anatomy of basal ganglia disorders. Trends Neurosci 12 (1989), 366-375.
5. Alexander, GE, Crutcher, MD, Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 13 (1990), 266-271.
6. Asselin, MC, Soghomonian, JJ, Cote, PY, Parent, A, Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys. Neuroreport 5 (1994), 2137-2140.
7. Bassilana, F, Mace, N, Li, Q, Stutzmann, JM, et al. Unraveling substantia nigra sequential gene expression in a progressive MPTP-lesioned macaque model of Parkinson's disease. Neurobiol Dis 20 (2005), 93-103.
8. Berardelli, A, Rothwell, JC, Thompson, PD, Hallett, M, Pathophysiology of bradykinesia in Parkinson's disease. Brain 124 (2001), 2131-2146.
9. Bergstrom, BP, Garris, PA, “Passive stabilization” of striatal extracellular dopamine across the lesion spectrum encompassing the presymptomatic phase of Parkinson's disease: a voltammetric study in the 6-OHDA-lesioned rat. J Neurochem 87 (2003), 1224-1236.
10. Bernheimer, H, Birkmayer, W, Hornykiewicz, O, Jellinger, K, Seitelberger, F, Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations. J Neurol Sci 20 (1973), 415-455.
11. Bezard, E, Gross, CE, Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. Prog Neurobiol 55 (1998), 93-116.
12. Bezard, E, Gross, CE, Brotchie, JM, Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci 26 (2003), 215-221.
13. Bezard, E, Boraud, T, Bioulac, B, Gross, CE, Presymptomatic revelation of experimental parkinsonism. Neuroreport 8 (1997), 435-438.
14. Bezard, E, Boraud, T, Bioulac, B, Gross, CE, Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental parkinsonism. Neuroscience 81 (1997), 399-404.
15. Bezard, E, Boraud, T, Bioulac, B, Gross, CE, Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms. Eur J Neurosci 11 (1999), 2167-2170.
16. Bezard, E, Crossman, AR, Gross, CE, Brotchie, JM, Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. FASEB J 15 (2001), 1092-1094.
17. Bezard, E, Boraud, T, Bioulac, B, Gross, CE, Evolution of the multiunit activity of the basal ganglia in the course of experimental parkinsonism. Graybiel, A, Delang, M, Kitaï, S, (eds.) The Basal Ganglia VI, 2002, Kluwer Academic Publishers, New York, 107-116.
18. Bezard, E, Imbert, C, Deloire, X, Bioulac, B, Gross, CE, A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain Res 766 (1997), 107-112.
19. Bezard, E, Ravenscroft, P, Gross, CE, Crossman, AR, Brotchie, JM, Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Neurobiol Dis 8 (2001), 343-350.
20. Bezard, E, Jaber, M, Gonon, F, Boireau, A, Bloch, B, Gross, CE, Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse. Eur J Neurosci 12 (2000), 2892-2900.
21. Bezard, E, Dovero, S, Prunier, C, et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 21 (2001), 6853-6861.
22. Blanchard, V, Anglade, P, Dziewczapolski, G, Savasta, M, Agid, Y, Raisman-Vozari, R, Dopaminergic sprouting in the rat striatum after partial lesion of the substantia nigra. Brain Res 709 (1996), 319-325.
23. Boraud, T, Bezard, E, Bioulac, B, Gross, CE, Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain 124 (2001), 546-557.
24. Boulet, S, Mounayar, S, Poupard, A, et al. Behavioral recovery in MPTP-treated monkeys: neurochemical mechanisms studied by intrastriatal microdialysis. J Neurosci 28 (2008), 9575-9584.
25. Chefer, SI, Kimes, AS, Matochik, JA, et al. Estimation of D2-like receptor occupancy by dopamine in the putamen of hemiparkinsonian Monkeys. Neuropsychopharmacology 33 (2008), 270-278.
26. Cunnington, R, Iansek, R, Bradshaw, JL, Movement-related potentials in Parkinson's disease: external cues and attentional strategies. Mov Disord 14 (1999), 63-68.
27. DeLong, MR, Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13 (1990), 281-285.
28. Dentresangle, C, Le Cavorsin, M, Savasta, M, Leviel, V, Increased extracellular DA and normal evoked DA release in the rat striatum after a partial lesion of the substantia nigra. Brain Res 893 (2001), 178-185.
29. Ehringer, H, Hornykiewicz, O, Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems/[Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system.]. Klin Wochenschr 38 (1960), 1236-1239.
30. Eidelberg, D, Moeller, JR, Ishikawa, T, et al. Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET. J Nucl Med 36 (1995), 378-383.
31. Elsworth, JD, Taylor, JR, Sladek, JR Jr., Collier, TJ, Redmond, DE Jr., Roth, RH, Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment. Neuroscience 95 (2000), 399-408.
32. Escola, L, Michelet, T, Macia, F, Guehl, D, Bioulac, B, Burbaud, P, Disruption of information processing in the supplementary motor area of the MPTP-treated monkey: a clue to the pathophysiology of akinesia?. Brain 126 (2003), 95-114.
33. Finkelstein, DI, Stanic, D, Parish, CL, Tomas, D, Dickson, K, Horne, MK, Axonal sprouting following lesions of the rat substantia nigra. Neuroscience 97 (2000), 99-112.
34. Fuxe, K, Agnati, LF, Two principal modes of electrochemical communication in the brain: volume versus wiring transmission. Fuxe, K, Agnati, LF, (eds.) Volume Transmission in the Brain: Novel Mechanisms for Neural Transmission, 1991, Raven Press, New-York, 1-9.
35. Garris, PA, Walker, QD, Wightman, RM, Dopamine release and uptake rates both decrease in the partially denervated striatum in proportion to the loss of dopamine terminals. Brain Res 753 (1997), 225-234.
36. Gaspar, P, Febvret, A, Colombo, J, Serotonergic sprouting in primate MTP-induced hemiparkinsonism. Exp Brain Res 96 (1993), 100-106.
37. Hassler, R, Zur Pathologie der Paralysis Agitans und des postenzephalitischen Parkinsonismus. J Psychol Neurol 48 (1938), 387-476.
38. Herrero, MT, Augood, SJ, Hirsch, EC, Javoy-Agid, F, Luquin, MR, Agid, Y, Obeso, JA, Emson, PC, Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience 68 (1995), 1189-1198.
39. Herrero, MT, Levy, R, Ruberg, M, et al. Consequence of nigrostriatal denervation and l-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum. Neurology 47 (1996), 219-224.
40. Hirsch, EC, Perier, C, Orieux, G, et al. Metabolic effects of nigrostriatal denervation in basal ganglia. Trends Neurosci 23 (2000), S78–S85.
41. Hornykiewicz, O, Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms. Adv Neurol 60 (1993), 140-147.
42. Hornykiewicz, O, Biochemical aspects of Parkinson's disease. Neurology 51 (1998), S2–S9.
43. Huang, C, Tang, C, Feigin, A, Lesser, M, Ma, Y, Pourfar, M, Dhawan, V, Eidelberg, D, Changes in network activity with the progression of Parkinson's disease. Brain 130 (2007), 1834-1846.
44. Jan, C, Francois, C, Tande, D, Yelnik, J, Tremblay, L, Agid, Y, Hirsch, E, Dopaminergic innervation of the pallidum in the normal state, in MPTP-treated monkeys and in parkinsonian patients. Eur J Neurosci 12 (2000), 4525-4535.
45. Javoy-Agid, F, Hirsch, EC, Dumas, S, Duyckaerts, C, Mallet, J, Agid, Y, Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson's disease: an in situ hybridization study. Neuroscience 38 (1990), 245-253.
46. Jenkins, IH, Fernandez, W, Playford, ED, Lees, AJ, Frackowiak, RS, Passingham, RE, Brooks, DJ, Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann Neurol 32 (1992), 749-757.
47. Joyce, JN, Smutzer, G, Whitty, CJ, Myers, A, Bannon, MJ, Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease. Mov Disord 12 (1997), 885-897.
48. Leblois, A, Meissner, W, Bezard, E, Bioulac, B, Gross, CE, Boraud, T, Temporal and spatial alterations in GPi neuronal encoding might contribute to slow down movement in Parkinsonian monkeys. Eur J Neurosci 24 (2006), 1201-1208.
49. Leblois, A, Meissner, W, Bioulac, B, Gross, CE, Hansel, D, Boraud, T, Late emergence of synchronized oscillatory activity in the pallidum during progressive Parkinsonism. Eur J Neurosci 26 (2007), 1701-1713.
50. Lee, CS, Samii, A, Sossi, V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 47 (2000), 493-503.
51. Levy, R, Herrero, MT, Ruberg, M, et al. Effects of nigrostriatal denervation and l-dopa therapy on the GABAergic neurons in the striatum in MPTP-treated monkeys and Parkinson's disease: an in situ hybridization study of GAD67 mRNA. Eur J Neurosci 7 (1995), 1199-1209.
52. Maneuf, YP, Mitchell, IJ, Crossman, AR, Brotchie, JM, On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus. Exp Neurol 125 (1994), 65-71.
53. Mitchell, IJ, Clarke, CE, Boyce, S, Robertson, RG, Peggs, D, Sambrook, MA, Crossman, AR, Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 32 (1989), 213-226.
54. Morissette, M, Grondin, R, Goulet, M, Bedard, PJ, Di Paolo, T, Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists. J Neurochem 72 (1999), 682-692.
55. Mounayar, S, Boulet, S, Tande, D, et al. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery. Brain 130 (2007), 2898-2914.
56. Obeso, JA, Rodriguez-Oroz, MC, Rodriguez, M, Lanciego, JL, Artieda, J, Gonzalo, N, Olanow, CW, Pathophysiology of the basal ganglia in Parkinson's disease. Trends in Neurosciences 23 (2000), S8–S19.
57. Obeso, JA, Rodriguez-Oroz, M, Marin, C, et al. The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 62 (2004), S17–S30.
58. Onn, SP, West, AR, Grace, AA, Dopamine-mediated regulation of striatal neuronal and network interactions. Trends Neurosci 23 (2000), S48–S56.
59. Onn, SP, Berger, TW, Stricker, EM, Zigmond, MJ, Effects of intraventricular 6-hydroxydopamine on the dopaminergic innervation of striatum: histochemical and neurochemical analysis. Brain Res 376 (1986), 8-19.
60. Orieux, G, Francois, C, Feger, J, Hirsch, EC, Consequences of dopaminergic denervation on the metabolic activity of the cortical neurons projecting to the subthalamic nucleus in the rat. J Neurosci 22 (2002), 8762-8770.
61. Orieux, G, Francois, C, Feger, J, Yelnik, J, Vila, M, Ruberg, M, Agid, Y, Hirsch, EC, Metabolic activity of excitatory parafascicular and pedunculopontine inputs to the subthalamic nucleus in a rat model of Parkinson's disease. Neuroscience 97 (2000), 79-88.
62. Pahapill, PA, Lozano, AM, The pedunculopontine nucleus and Parkinson's disease. Brain 123:Pt 9 (2000), 1767-1783.
63. Palombo, E, Porrino, LJ, Bankiewicz, KS, Crane, AM, Sokoloff, L, Kopin, IJ, Local cerebral glucose utilization in monkeys with hemiparkinsonism induced by intracarotid infusion of the neurotoxin MPTP. J Neurosci 10 (1990), 860-869.
64. Parent, A, Cote, PY, Lavoie, B, Chemical anatomy of primate basal ganglia. Prog Neurobiol 46 (1995), 131-197.
65. Parish, CL, Finkelstein, DI, Tripanichkul, W, Satoskar, AR, Drago, J, Horne, MK, The role of interleukin-1, interleukin-6, and glia in inducing growth of neuronal terminal arbors in mice. J Neurosci 22 (2002), 8034-8041.
66. Perez, XA, Parameswaran, N, Huang, LZ, O'Leary, KT, Quik, M, Pre-synaptic dopaminergic compensation after moderate nigrostriatal damage in non-human primates. J Neurochem 105 (2008), 1861-1872.
67. Pessiglione, M, Guehl, D, Rolland, AS, Francois, C, Hirsch, EC, Feger, J, Tremblay, L, Thalamic neuronal activity in dopamine-depleted primates: evidence for a loss of functional segregation within basal ganglia circuits. J Neurosci 25 (2005), 1523-1531.
68. Pifl, C, Hornykiewicz, O, Dopamine turnover is upregulated in the caudate/putamen of asymptomatic MPTP-treated rhesus monkeys. Neurochem Int 49 (2006), 519-524.
69. Playford, ED, Jenkins, IH, Passingham, RE, Frackowiak, RS, Brooks, DJ, Impaired activation of frontal areas during movement in Parkinson's disease: a PET study. Adv Neurol 60 (1993), 506-510.
70. Rascol, O, Sabatini, U, Chollet, F, Celsis, P, Montastruc, JL, Marc-Vergnes, JP, Rascol, A, Supplementary and primary sensory motor area activity in Parkinson's disease. Regional cerebral blood flow changes during finger movements and effects of apomorphine. Arch Neurol 49 (1992), 144-148.
71. Rascol, O, Sabatini, U, Brefel, C, et al. Cortical motor overactivation in parkinsonian patients with l-dopa-induced peak-dose dyskinesia. Brain 121:Pt 3 (1998), 527-533.
72. Robinson, TE, Mocsary, Z, Camp, DM, Whishaw, IQ, Time course of recovery of extracellular dopamine following partial damage to the nigrostriatal dopamine system. J Neurosci 14 (1994), 2687-2696.
73. Rodriguez, M, Gonzalez, J, Sabate, M, Obeso, J, Pereda, E, Firing regulation in dopaminergic cells: effect of the partial degeneration of nigrostriatal system in surviving neurons. Eur J Neurosci 18 (2003), 53-60.
74. Rothblat, DS, Schneider, JS, Regional differences in striatal dopamine uptake and release associated with recovery from MPTP-induced parkinsonism: an in vivo electrochemical study. J Neurochem 72 (1999), 724-733.
75. Schneider, JS, Kovelowski, CJ 2nd, Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Res 519 (1990), 122-128.
76. Schneider, JS, Pope-Coleman, A, Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey. Neurodegeneration 4 (1995), 245-255.
77. Schneider, JS, Decamp, E, Wade, T, Striatal preproenkephalin gene expression is upregulated in acute but not chronic parkinsonian monkeys: implications for the contribution of the indirect striatopallidal circuit to parkinsonian symptomatology. J Neurosci 19 (1999), 6643-6649.
78. Seeman, P, Weinshenker, D, Quirion, R, et al. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc Natl Acad Sci USA 102 (2005), 3513-3518.
79. Shink, E, Bevan, MD, Bolam, JP, Smith, Y, The subthalamic nucleus and the external pallidum: two tightly interconnected structures that control the output of the basal ganglia in the monkey. Neuroscience 73 (1996), 335-357.
80. Singh, N, Pillay, V, Choonara, YE, Advances in the treatment of Parkinson's disease. Progress in Neurobiology 81 (2007), 29-44.
81. Snyder, GL, Keller, RW Jr., Zigmond, MJ, Dopamine efflux from striatal slices after intracerebral 6-hydroxydopamine: evidence for compensatory hyperactivity of residual terminals. J Pharmacol Exp Ther 253 (1990), 867-876.
82. Song, DD, Haber, SN, Striatal responses to partial dopaminergic lesion: evidence for compensatory sprouting. J Neurosci 20 (2000), 5102-5114.
83. Sossi, V, Dinelle, K, Topping, GJ, et al. Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in-vivo imaging study. J Neurochem 109:1 (2009), 85-92.
84. Stanic, D, Finkelstein, DI, Bourke, DW, Drago, J, Horne, MK, Timecourse of striatal re-innervation following lesions of dopaminergic SNpc neurons of the rat. Eur J Neurosci 18 (2003), 1175-1188.
85. Takeuchi, Y, Sawada, T, Blunt, S, Jenner, P, Marsden, CD, Effects of 6-hydroxydopamine lesions of the nigrostriatal pathway on striatal serotonin innervation in adult rats. Brain Res 562 (1991), 301-305.
86. Tong, ZY, Kingsbury, AE, Foster, OJ, Up-regulation of tyrosine hydroxylase mRNA in a sub-population of A10 dopamine neurons in Parkinson's disease. Brain Res Mol Brain Res 79 (2000), 45-54.
87. Uhl, GR, Walther, D, Mash, D, Faucheux, B, Javoy-Agid, F, Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Ann Neurol 35 (1994), 494-498.
88. Vila, M, Levy, R, Herrero, MT, Ruberg, M, Faucheux, B, Obeso, JA, Agid, Y, Hirsch, EC, Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in situ hybridization study of cytochrome oxidase subunit I mRNA. J Neurosci 17 (1997), 765-773.
89. Vila, M, Perier, C, Feger, J, et al. Evolution of changes in neuronal activity in the subthalamic nucleus of rats with unilateral lesion of the substantia nigra assessed by metabolic and electrophysiological measurements. Eur J Neurosci 12 (2000), 337-344.
90. Whone, AL, Moore, RY, Piccini, PP, Brooks, DJ, Plasticity of the nigropallidal pathway in Parkinson's disease. Ann Neurol 53 (2003), 206-213.
91. Zhang, WQ, Tilson, HA, Nanry, KP, Hudson, PM, Hong, JS, Stachowiak, MK, Increased dopamine release from striata of rats after unilateral nigrostriatal bundle damage. Brain Res 461 (1988), 335-342.
92. Zhou, FC, Bledsoe, S, Murphy, J, Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain. Brain Res 556 (1991), 108-116.
93. Zigmond, MJ, Do compensatory processes underlie the preclinical phase of neurodegenerative disease? Insights from an animal model of parkinsonism. Neurobiol Dis 4 (1997), 247-253.
94. Zigmond, MJ, Stricker, EM, Recovery of feeding and drinking by rats after intraventricular 6-hydroxydopamine or lateral hypothalamic lesions. Science 182 (1973), 717-720.
95. Zigmond, MJ, Abercrombie, ED, Berger, TW, Grace, AA, Stricker, EM, Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 13 (1990), 290-296.
96. Zigmond, SH, Recent quantitative studies of actin filament turnover during cell locomotion. Cell Motil Cytoskeleton 25 (1993), 309-316.
97. Zoli, M, Jansson, A, Sykova, E, Agnati, LF, Fuxe, K, Volume transmission in the CNS and its relevance for neuropsychopharmacology. Trends Pharmacol Sci 20 (1999), 142-150.